×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
GlobeNewswire
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused...
1 day ago
Viracta Therapeutics appoints Michael Faerm as CFO By Investing.com
Investing.com
SAN DIEGO - Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company, announced today the immediate appointment of Michael...
1 day ago
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Yahoo Finance
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused...
3 months ago
Viracta Therapeutics Welcomes New CFO and Outlines Compensation - TipRanks.com
Tipranks
Viracta Therapeutics (VIRX) has issued an announcement. Michael Faerm has been appointed as the new Chief Financial Officer of Viracta...
2 days ago
Viracta Therapeutics (NASDAQ:VIRX) Shares Down 7.9%
Defense World
Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Free Report)'s stock price was down 7.9% during trading on Friday . The company traded as low...
4 days ago
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R)...
6 days ago
Viracta Therapeutics Loses Finance, Operating Chief
MarketWatch
By Ben Glickman Viracta Therapeutics said its finance and operating chief Dan Chevallard has resigned from his dual roles to pursue other...
1 month ago
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort ...
Yahoo Finance
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter...
2 months ago
Sunesis: Q1 Earnings Snapshot
Milford Mirror
CARDIFF, Calif. (AP) — CARDIFF, Calif. (AP) — Viracta Therapeutics, Inc. (VIRX) on Thursday reported a loss of $9.1 million in its first...
6 days ago
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of ...
Yahoo Finance
First orphan drug designation for Nana-val granted in EBV+ solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted...
5 months ago